Healthcare
Roche Commits Up to $2 Billion to Atavistik’s Small-Molecule Discovery Platform
Roche’s agreement with Atavistik Bio targets cardiovascular, kidney and metabolic disease, extending Big Pharma’s push to source novel drug platforms…
Roche’s agreement with Atavistik Bio targets cardiovascular, kidney and metabolic disease, extending Big Pharma’s push to source novel drug platforms…
Read next